The stock of Eli Lilly has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buy, two ...

Shares of Eli Lilly & Co. LLY rallied 2.89% to $798.89 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to 6,358.91 ...

What I’m thinking, as someone who owns Eli Lilly for the Charitable Trust and who wishes I owned PepsiCo, is that there might ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

Eli Lilly closed at $1.87, ranked 34th in trading volume on July 22, 2025. BMO Capital remains bullish, reiterating a buy ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

On Thursday’s episode of Mad Money, host Jim Cramer turned his focus to large-cap stocks that surged by $10 or more in a single day.

FBCG, a large-cap growth ETF, excels in bullish markets but struggles in downturns. Learn why it's rated Hold amid current ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.